15:37:32 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2025-02-14 Bokslutskommuniké 2024
2024-11-14 Kvartalsrapport 2024-Q3
2024-08-16 Kvartalsrapport 2024-Q2
2024-05-17 Kvartalsrapport 2024-Q1
2024-03-01 Ordinarie utdelning CSMED 0.00 DKK
2024-02-29 Årsstämma 2024
2024-02-14 Bokslutskommuniké 2023
2023-12-15 Ordinarie utdelning CSMED 0.00 DKK
2023-07-18 Kvartalsrapport 2023-Q3
2023-05-17 Kvartalsrapport 2023-Q2
2023-04-14 Extra Bolagsstämma 2023
2023-02-17 Kvartalsrapport 2023-Q1
2023-02-14 Årsstämma 2023
2023-02-10 Ordinarie utdelning CSMED 0.00 DKK
2022-11-18 Bokslutskommuniké 2022
2022-08-13 Kvartalsrapport 2022-Q3
2022-05-20 Kvartalsrapport 2022-Q2
2022-02-18 Kvartalsrapport 2022-Q1
2021-12-10 Ordinarie utdelning CSMED 0.00 DKK
2021-12-09 Årsstämma 2022
2021-11-18 Bokslutskommuniké 2021

Beskrivning

LandDanmark
ListaSpotlight DK
SektorHälsovård
IndustriLäkemedel & Handel
CS Medica är ett danskt medicintekniskt bolag, dedikerat till läkemedelsforskning, utveckling, tillverkning och global kommersialisering. Bolaget blandar vetenskap och natur för att förbättra patienters liv med cannabinoidterapier för smärtlindring, och för att hantera autoimmuna och stressrelaterade symtom. Globalt erbjuder CS Medica CBD-behandlingar över disk (OTC), inklusive patenterade medicinska produkter, MHRA och MDR-registrerade artiklar, under varumärket CANNASEN® eller med egen märkning.
2022-08-18 16:37:51

CS MEDICA A/S ("CS MEDICA" or the "Company") need to inform the market that they aim to secure and capitalize on their first mover advantages by securing the necessary capital, hence they are intensifying their effort to close a Direct Issue, on a share price goal of 31,50 DKK with new investors.

CS MEDICA's goal is to become a leading company in the cannabis medical treatment industry, by utilizing its first mover advantages. This status will be ensured, through accelerated growth and multiple revenue streams based on a product portfolio for autoimmune and stress-related disorders, benefiting patients and healthcare providers worldwide.

As mentioned at the webinar held on Tuesday 16/8 2022, the speed at which this can be achieved depends on the funding available. The company secured funding to maintain momentum and controlled growth through the finalized bridge loan of DKK 6 million and their TO 1 warrants. However, further funding is needed to fully capitalize on their first mover advantage and accelerate their global market expansion and product development. Hence the company intensifies their focus on finalizing a Direct Issue, with a share price goal of 31,50 DKK per share. 

CS MEDICA's current goal is to close a Direct issue of a total number of shares between 158.730 and 1.904.762, corresponding to a capital injection of 5 to 60 MDKK.
 

Disclaimer
Some statements may contain forward-looking information. All statements, other than of historical fact, that address activities, events, or developments that the Company believes, expects, or anticipates will or may occur in the future (including, without limitation, statements regarding potential distributor agreements) are forward-looking statements. Forward-looking statements are subject to several risks and uncertainties, many of which are beyond the Company's ability to control or predict, which may cause the actual results of the Company to differ materially from those discussed in the forwardlooking statements.

Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described, there may be other factors that cause results or events not to be as anticipated, estimated or intended. The forward-looking statements included in this report are made as of the date of this press release and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

[1] Meeting a market value of over SEK 150 million, a free float of 25%, accounting according to IFRS and follows the code for corporate governance.